摘要
小细胞肺癌(SCLC)是一种肺神经内分泌肿瘤,占肺癌总数的15%～20%,其特点是恶性程度高,容易出现转移,大多数病例确诊时已为晚期,预后差,化疗、放疗是其主要的治疗方法,而且处以平台期。早期的治疗反应比较好,之后会出现耐药导致病情进展,再次治疗效果差,所以需要新的有效的治疗方法。随着非小细胞肺癌靶向药物治疗的兴起,也相继研发出一些针对小细胞肺癌的靶向药物,如基因遗传、血管生成、凋亡通路等抑制剂。本文主要对小细胞肺癌靶向药物治疗进展作一综述。
Small cell lung cancer(SCLC) is a kind of lung neuroendocrine tumor,about 15% to 20% of the total lung cancer,its characteristics are high degree of malignancy,easy to metastasis,most cases have been diagnosed as late,poor prognosis,chemotherapy,radiotherapy is the main treatment method, but also in the platform period.The early treatment response is relatively good,and then drug resistance will lead to the progression of the disease,and the treatment effect will be poor again,so new and effective treatment is needed.With the rise of targeted drug therapy for non-small cell lung cancer,some targeted drugs have been developed for small cell lung cancer,such as inhibitors of genetic inheritance,angiogenesis and apoptosis pathways.This article reviews the progress of targeted drug therapy for small cell lung cancer.
作者
周毅
ZHOU Yi(The Seventh Affiliated Hospital of Guangxi Medical University,Wuzhou Workers’Hospital,Wuzhou 543001,China)
出处
《中外医学研究》
2019年第12期186-188,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
小细胞肺癌
靶向药物
治疗策略
恶性肿瘤
Small cell lung cancer
Targeted drugs
Treatment strategy
Malignant tumor
